A population-based cohort study showed that early use of nirmatrelvir-ritonavir significantly improved long-term post-COVID outcomes.

Greater benefits of immediate nirmatrelvir-ritonavir initiation for post-COVID outcomes: a population-based retrospective cohort study

Data from a phase 2 randomized controlled clinical trial show ensitrelvir accelerated viral clearance in patients with early symptomatic COVID-19.

Trial data show ensitrelvir has potent antiviral activity against COVID-19

A real-world study in Québec found that nirmatrelvir-ritonavir significantly reduced hospitalization rates among high-risk COVID-19 outpatients.

Title: Nirmatrelvir-Ritonavir Reduces COVID-19 Hospitalization Risk in High-Risk Outpatients

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company pioneering innovative therapies for viral diseases, is pleased to announce the successful completion of its second randomized double-blind, placebo-controlled clinical trial for its leading broad-spectrum antiviral drug candidate, ProLectin-M. Data from the trial is expected to inform both the CDSCO for a phase 3 trial design and will also be submitted to the FDA pursuant to their request.

antiviral news

Press Releases in the global landscape